Patients with baclofen pumps may safely undergo transcutaneous spinal stimulation

Kessler pilot study shows pump delivery system unaffected although interference with communication may occur during the pump’s log transmission

East Hanover, NJ. March 21, 2023. Researchers from Kessler Foundation and Kessler Institute for Rehabilitation (collectively “Kessler”) conducted the first prospective study to assess whether transcutaneous spinal stimulation (TSS) interacts with implanted intrathecal baclofen (ITB) pump delivery systems for managing spasticity. The article, "Transcutaneous spinal stimulation in patients with intrathecal baclofen pump delivery system: A preliminary safety study," (doi: 10.3389/fnins.2022.1075293), was published December 21, 2022, in Frontiers in Neuroscience. It is available open access at: https://www.frontiersin.org/articles/10.3389/fnins.2022.1075293/full

The pilot study was conducted at the Tim and Caroline Reynolds Center for Spinal Stimulation by John Lopez, DO, Gail Forrest, PhD, Einat Engel-Haber, MD, Brittany Snider, MD, Kam Momeni, PhD, Manikandan Ravi, MS, and Steven Kirshblum, MD.

Due to a lack of adequate data on how spinal stimulation affects intrathecal medication delivery, individuals with pump delivery systems are often excluded from TSS trials. In this study, Kessler team members tested their hypothesis that TSS would not interfere with the ITB pump system. The five study participants were adults with chronic traumatic spinal cord injury, each with an anteriorly implanted ITB pump delivery system (Medtronic SynchroMed™ II).

Each participant underwent two trials of TSS: the first to establish intensity of lower thoracic stimulation as measured by surface electromyography of the lower extremity muscles, and the second to deliver 30 minutes of moderate-intensity stimulation. To monitor pump function, the pump was interrogated before, during, and after stimulation.

Results revealed no evidence for pump dysfunction as measured by pump log evaluations. Interference of the communication between the interrogator and the pump was evidenced by lapses in log transmission during TSS, most likely due to transient electromagnetic interference. One participant had an adverse event that was likely unrelated to the TSS, but rather related to a bladder issue and underlying urinary tract infection.

“Based on our preliminary findings, individuals with implanted baclofen pumps may be considered for TSS studies involving the low thoracic spine,” said Dr. Lopez, staff physiatrist at Kessler Institute for Rehabilitation. “While communication between the pump and its interrogator may be briefly affected, there was no evidence that medication delivery was disrupted.”

Given the potential benefits of TSS in the population with spinal cord injury, further research is warranted, according to Dr. Kirshblum, chief medical officer of Kessler Institute for Rehabilitation and Kessler Foundation and director of Spinal Cord Injury Services at Kessler Institute for Rehabilitation. “We need to study the effects of various patterns and intensities of transcutaneous stimulation in patients with baclofen pumps,” he noted, “as well as the effects of repeated sessions and stimulation at multiple sites.”



Funding: Tim and Caroline Reynolds

About Kessler Foundation

Kessler Foundation, a major nonprofit organization in the field of disability, is a global leader in rehabilitation research. Our scientists seek to improve cognition, mobility, and long-term outcomes, including employment, for adults and children with neurological and developmental disabilities of the brain and spinal cord including traumatic brain injury, spinal cord injury, stroke, multiple sclerosis, and autism. Kessler Foundation also leads the nation in funding innovative programs that expand opportunities for employment for people with disabilities.

About Select Medical

Select Medical is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States based on number of facilities. As of December 31, 2022, Select Medical operated 103 critical illness recovery hospitals in 28 states, 31 rehabilitation hospitals in 12 states, and 1,928 outpatient rehabilitation clinics in 39 states and the District of Columbia. Concentra operated 540 occupational health centers in 41 states. At December 31, 2022, Select Medical had operations in 46 states and the District of Columbia. For more information, visit: www.selectmedical.com